Chronic Kidney Disease in Cancer Survivors.


Journal

Advances in chronic kidney disease
ISSN: 1548-5609
Titre abrégé: Adv Chronic Kidney Dis
Pays: United States
ID NLM: 101209214

Informations de publication

Date de publication:
09 2021
Historique:
received: 21 06 2021
revised: 12 10 2021
accepted: 25 10 2021
entrez: 22 2 2022
pubmed: 23 2 2022
medline: 22 3 2022
Statut: ppublish

Résumé

As breakthroughs in cancer care are leading to improved long-term outcomes in a subset of advanced cancers, there is a growing population of long-term cancer survivors that are at risk of long-term complications. In this review, we summarize what is known about chronic kidney disease in cancer survivors, focusing on the following high-risk groups: survivors of childhood cancers, stem cell transplant recipients, patients with renal cell carcinoma, patients exposed to cisplatin and other nephrotoxic chemotherapies, and patients receiving immunotherapy for cancer. As new anticancer therapies are developed, more research is needed to understand the long-term risks of kidney function decline and to devise methods to prevent chronic kidney disease.

Identifiants

pubmed: 35190113
pii: S1548-5595(21)00128-2
doi: 10.1053/j.ackd.2021.10.007
pii:
doi:

Substances chimiques

Cisplatin Q20Q21Q62J

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

469-476.e1

Informations de copyright

Copyright © 2021 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Auteurs

Meghan Lee (M)

Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

Qiyu Wang (Q)

Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

Rimda Wanchoo (R)

Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY.

Meghana Eswarappa (M)

Division of Nephrology, Department of Medicine, Icahn School of Medicine at the Mount Sinai Hospital, New York, NY.

Priya Deshpande (P)

Division of Nephrology, Department of Medicine, Icahn School of Medicine at the Mount Sinai Hospital, New York, NY.

Meghan E Sise (ME)

Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA. Electronic address: msise@partners.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH